BioMed Research International / 2015 / Article / Tab 3

Research Article

Assessment of Duration of Staying Free from Acquiring Rehappening Opportunistic Infections among Pre-ART People Living with HIV/AIDS between 2008 and 2013

Table 3

The cumulative incidence of diagnosing OI, Kaplan Meier estimation of median duration of not acquiring OI recurrence and cox proportional hazard model of the association between characteristics and OI recurrence among PLWHA in Debre Markos town between 2007 and 2013.

VariablesDiagnosis of recurrence OIMedian KMS CHR (95% CI)AHR (95% CI)
Yes (%)No (%)

Marital status
 Married101 (39.3)29 (34.5)6011
 Single 68 (26.5)11 (13.1)461.65 (1.21–2.26)1.19 (0.72–1.96)
 Divorced 60 (23.3)32 (38.1)641.02 (0.74–1.41)0.57 (0.33–0.99)
 Widowed28 (10.9)12 (14.3)421.69 (1.10–2.59)1.64 (0.79–3.40)
Educational status
 Not educated 110 (42.8)43 (51.2)5511
 Grades 1–882 (31.9)16 (19)411.06 (0.79–1.41)1.17 (0.70–1.94)
 Grades 9–1244 (17.1)14 (16.7)550.84 (0.59–1.19)1.38 (0.71–2.68)
 Above grade 12 21 (8.2)11 (13.1)670.49 (0.30–0.80)1.55 (0.69–3.47)
Occupational status
 Unemployed221 (86)70 (83.3)5311
 Employed 36 (14)14 (16.7)760.48 (0.33–0.69)0.34 (0.16–0.71)
Functional statusB.
 Working 206 (80.2)77 (91.7)6011
 Ambulatory/bed-ridden51 (19.8)7 (8.3)321.7 (1.25–2.32)1.59 (0.81–3.12)
Functional statusF.
 Working 215 (83.7)82 (97.6)6011
 Ambulatory/bed-ridden42 (16.3)2 (2.4)371.65 (1.17–2.31)0.97 (0.52–1.81)
Number of OIs treated at base line
 1203 (79)62 (73.8)5911
 ≥254 (21)22 (26.2)441.38 (1.01–1.87)1.19 (0.69–2.07)
Prophylaxis adherenceB.
 Good 170 (91.4)55 (94.8)6411
 Fair 6 (3.2)0 (0)432.69 (1.19–6.13)14.92 (1.03–215)
 Poor10 (5.4)3 (5.2)231.76 (0.92–3.35)5.96 (1.21–29.41)
Prophylaxis adherenceF.
 Good173 (88.3)58 (98.3)6411
 Fair9 (4.6)0 (0)551.06 (0.54–2.08)5.39 (1.77–16.36)
 Poor14 (7.1)1 (1.7)222.2 (1.27–3.82)5.79 (1.86–17.98)
Prophylaxis exposureB.
 No71 (27.6)26 (31)3711
 Yes 186 (72.4)58 (69)630.64 (0.49–0.85)0.31 (0.19–0.49)
CD4 count (cells/μL)F.
 ≤1004 (2.2)1 (1.4)1711
 101–19919 (10.6)3 (4.2)600.19 (0.06–0.58)0.12 (0.029–0.49)
 200–35050 (27.8)27 (37.5)690.14 (0.048–0.39)0.21 (0.057–0.79)
 351–49958 (32.2)24 (33.3)660.17 (0.058–0.47)0.16 (0.045–0.59)
 ≥50049 (27.2)17 (23.6)700.13 (0.046–0.38)0.17 (0.46–0.62)
Hemoglobin value (g/dL)B.
 <1061 (31.1)5 (16.7)2611
 ≥10135 (68.9)25 (83.3)530.55 (0.40–0.75)0.49 (0.25–0.97)
Body mass index (kg/m2)F.
 ≤18.4122 (47.7)36 (42.9)4611
 18.5–22.9103 (40.2)35 (41.7)540.93 (0.71–1.21)0.89 (0.54–1.46)
 ≥2331 (12.1)13 (15.5)690.54 (0.37–0.79)0.61 (0.33–1.14)
Herpes Zoster diagnosisB.
 No 202 (78.6)73 (86.9)5511
 Yes 55 (21.4)11 (13.1)481.38 (1.02–1.86)1.18 (0.65–2.13)
Wasting syndrome diagnosisB.
 No 247 (96.1)84 (100)5511
 Yes10 (3.9)0 (0)232.39 (1.21–4.34)1.29 (0.36–4.71)

BBase line value.
FFollow-up value.
KMS: Kaplan Meier survival in weeks.
CHR: crude hazard rate.
AHR: Adjusted hazard rate.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.